Ionis Pharmaceuticals IONS Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's total liabilities?
- Ionis Pharmaceuticals (IONS) reported total liabilities of $2.96B in Q1 2026.
- How has Ionis Pharmaceuticals's total liabilities changed year-over-year?
- Ionis Pharmaceuticals's total liabilities increased by 26.6% year-over-year, from $2.34B to $2.96B.
- What is the long-term trend for Ionis Pharmaceuticals's total liabilities?
- Over 5 years (2020 to 2025), Ionis Pharmaceuticals's total liabilities has grown at a 13.0% compound annual growth rate (CAGR), from $1.65B to $3.03B.
- What does total liabilities mean?
- The total amount of all money and obligations the company owes to others.
- How do you interpret total liabilities?
- A high ratio of total liabilities to equity may indicate higher financial risk, while a decreasing trend suggests deleveraging.
- How does total liabilities compare across companies?
- Standardized metric used to assess the overall financial health and debt burden of a company relative to its peers.